BREAKING NEWS:  VTAMA® (tapinarof) cream, 1%  Learn More

The Dermavant Sciences logo.

Featured Searches

VTAMA® (tapinarof) cream, 1%

In the News

Careers

Leadership Team

Most Searched Tags

Clinical Trials Field Medical Director Compliance Program Medical Affairs Culture
Back to Medical Affairs

INDEPENDENT MEDICAL EDUCATION GRANT REQUEST

Review of educational grant submissions is suspended through the end of the year. New submissions will be considered at that time.

Dermavant Sciences will consider funding grant requests that support independent, accredited or non-accredited medical education programs/events for healthcare professionals.

Grants must be independent of commercial bias and non-promotional in nature.

Grant requests may be submitted to support live events, web-based education, or print material.

Please submit all grant requests online to the Dermavant Medical Education Portal

Please direct any questions via email to grants@dermavant.com.

Submit a Grant Request

You are now leaving Dermavant.com

You are now leaving www.dermavant.com. Links to sites outside of Dermavant are provided as a resource to the viewer. Dermavant accepts no responsibility for the content of linked sites.

You are now leaving Dermavant.com

You are now leaving www.dermavant.com. Links to sites outside of Dermavant are provided as a resource to the viewer. Dermavant accepts no responsibility for the content of linked sites.

You are now leaving Dermavant.com

You are now leaving www.dermavant.com. Links to sites outside of Dermavant are provided as a resource to the viewer. Dermavant accepts no responsibility for the content of linked sites.

You are now leaving Dermavant.com

You are now leaving www.dermavant.com. Links to sites outside of Dermavant are provided as a resource to the viewer. Dermavant accepts no responsibility for the content of linked sites.

Important Safety Information

Indications: VTAMA® (tapinarof) cream, 1% is an aryl hydrocarbon receptor agonist indicated for:

  • the topical treatment of plaque psoriasis in adults.
  • the topical treatment of atopic dermatitis in adults and pediatric patients 2 years of age and older.

Adverse Events: In plaque psoriasis, the most common adverse reactions (incidence ≥1%) were: red raised bumps around the hair pores (folliculitis); pain or swelling in the nose and throat (nasopharyngitis); skin rash or irritation, including itching and redness, peeling, burning, or stinging (contact dermatitis); headache; itching (pruritus); and flu (influenza).

Adverse Events: In atopic dermatitis, the most common adverse reactions (incidence ≥1%) were: upper respiratory tract infection; red raised bumps around the hair pores (folliculitis); lower respiratory tract infection; headache; asthma; vomiting; ear infection; pain in extremity; and stomach-area (abdominal) pain.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

See full Prescribing Information and Patient Information.